Skip to main content
. 2014 Aug 31;21(2):307–313. doi: 10.1007/s12253-014-9822-6

Table 2.

Associations of nucleotide variants identified by GWAS with the risk of ovarian cancer

Chr rs no. Allelesa MAFb Genotypes casesc Genotypes controlsc pgenotypic value ptrend value pallelic value ORdominant (95 % CI)d; p value ORrecessive(95 % CI)e; p value
2q31 rs2072590 G / t 0.35 All 116 / 115 / 41 198 / 207 / 59 0.633 0.652 0.686 1.001 (0.740–1.355); 0.995 1.218 (0.793–1.873); 0.368
Serous 38 / 43 / 16 0.579 0.343 0.379 1.156 (0.739–1.808); 0.526 1.356 (0.743–2.475); 0.320
Mucinous 11 / 16 / 3 0.644 0.797 0.905 1.286 (0.598–2.764); 0.519 0.763 (0.224–2.594); 1.000f
Endometrioid 28 / 15 / 10 0.067 0.690 0.762 0.665 (0.376–1.175) ; 0.159 1.596 (0.761–3.348); 0.212
Clear cell 9 / 11 / 6 0.301 0.183 0.230 1.406 (0.614–3.221); 0.418 2.059 (0.794–5.338); 0.130
Mixed 11 / 10 / 3 0.952 0.813 0.933 0.880 (0.386–2.005); 0.760 0.981 (0.284–3.390); 1.000f
Solid tumor 7 / 9 / 1 0.645 0.750 0.891 1.063 (0.398–2.843); 0.903 0.429 (0.056–3.297); 0.708f
Untyped 12 / 11 / 2 0.748 0.471 0.566 0.806 (0.360–1.806); 0.600 0.597 (0.137–2.598); 0.756f
3q25 rs2665390 c / T 0.09 All 218 / 50 / 2 380 / 77 / 5 0.744 0.715 0.784 1.105 (0.742–1.625); 0.610 0.682 (0.131–3.542); 1.000f
Serous 75 / 20 / 1 0.619 0.389 0.463 1.298 (0.756–2.226); 0.343 0.962 (0.111–8.333); 1.000f
Mucinous 27 / 3 / 0 0.522 0.255 0.354f 0.515 (0.153–1.739); 0.452f N/A
Endometrioid 43 / 8 / 0 0.740 0.606 0.734 0.862 (0.391–1.903); 0.713 N/A
Clear cell 20 / 5 / 1 0.425 0.344 0.471 1.390 (0.541–3.571); 0.492 3.656 (0.411–32.504); 0.281f
Mixed 17 / 7 / 0 0.261 0.240 0.082 1.908 (0.766–4.751); 0.159 N/A
Solid tumor 15 / 3 / 0 0.906 0.829 0.400f 0.818 (0.234–2.856); 1.000f N/A
Untyped 21 / 4 / 0 0.867 0.740 0.791 0.883 (0.295–2.641); 1.000f N/A
8q24 rs10088218 a / G 0.12 All 223 / 44 / 4 357 / 100 / 7 0.214 0.120 0.137 0.718 (0.491–1.050); 0.086 0.978 (0.284–3.373); 1.000f
Serous 80 / 16 / 0 0.249 0.118 0.152 0.667 (0.374–1.190); 0.168 N/A
Mucinous 26 / 4 / 0 0.427 0.193 0.301f 0.513 (0.175–1.504); 0.265f N/A
Endometrioid 42 / 11 / 0 0.655 0.566 0.679 0.874 (0.435–1.757); 0.705 N/A
Clear cell 21 / 4 / 1 0.519 0.874 0.873 0.794 (0.293–2.158); 0.812f 2.611 (0.309–22.066); 0.356f
Mixed 19 / 3 / 2 0.036 0.642 0.805 0.878 (0.320–2.408); 1.000f 5.935 (1.164–30.263); 0.068f
Solid tumor 15 / 2 / 0 0.531 0.260 0.418f 0.445 (0.100–1.977); 0.383f N/A
Untyped 20 / 4 / 1 0.529 0.953 0.952 0.834 (0.306–2.276); 1.000f 2.720 (0.321–23.020); 0.345
8q24 rs10098821 C / t 0.11 All 233 / 34 / 3 363 / 94 / 6 0.028 0.014 0.016 0.576 (0.382–0.870); 0.008 0.856 (0.212–3.451); 1.000f
Serous 84 / 12 / 0 0.099 0.033 0.045 0.519 (0.272–0.988); 0.043 N/A
Mucinous 25 / 4 / 0 0.558 0.285 0.390f 0.581 (0.196–1.708); 0.481f N/A
Endometrioid 44 / 9 / 0 0.583 0.358 0.451 0.743 (0.351–1.576); 0.435f N/A
Clear cell 25 / 1 / 0 0.093 0.033 0.036f 0.145 (0.019–1.085); 0.025f N/A
Mixed 19 / 3 / 2 0.023 0.514 0.667 0.955 (0.348–2.623); 1.000f 6.924 (1.321–36.304); 0.054f
Solid tumor 16 / 1 / 0 0.293 0.122 0.165f 0.227 (0.030–1.732); 0.141f NA
Untyped 20 / 4 / 1 0.488 0.905 0.905 0.908 (0.332–2.479); 1.000f 3.174 (0.367–27.435); 0.310f
9p22 rs3814113 c / T 0.41 All 123 / 114 / 35 167 / 213 / 82 0.033 0.010 0.009 0.696 (0.505–0.930); 0.015 0.684 (0.446–1.050); 0.081
Serous 50 / 36 / 11 0.016 0.006 0.006 0.532 (0.342–0.827); 0.005 0.593 (0.303–1.160); 0.123
Mucinous 12 / 12 / 6 0.809 0.905 0.903 0.849 (0.399–1.806); 0.671 1.159 (0.459–2.925); 0.755
Endometrioid 19 / 24 / 9 0.996 0.936 0.935 0.983 (0.542–1.784); 0.956 0.970 (0.455–2.068); 0.937
Clear cell 12 / 11 / 3 0.524 0.257 0.310 0.661 (0.299–1.461); 0.303 0.605 (0.177–2/062); 0.596f
Mixed 9 / 12 / 3 0.800 0.656 0.762 0.944 (0.404–2.203); 0.893 0.662 (0.193–2.272); 0.782f
Solid tumor 10 / 7 / 1 0.178 0.064 0.085 0.453 (0.175–1.170); 0.094 0.273 (0.036–2.078); 0.335f
Untyped 11 / 12 / 2 0.422 0.226 0.277 0.721 (0.320–1.623); 0.427 0.403 (0.093–1.744); 0.282f
17q21 rs9303542 A / g 0.25 All 134 / 123 / 15 261 / 175 / 28 0.134 0.162 0.193 1.324 (0.981–1.788); 0.067 0.909 (0.476–1.734); 0.772
Serous 54 / 36 / 6 0.997 0.975 0.975 1.000 (0.642–1.558); 1.000 1.038 (0.418–2.581); 0.936
Mucinous 17 / 12 / 1 0.823 0.785 0.907 0.983 (0.467–2.072); 0.964 0.537 (0.071–4.089); 1.000f
Endometrioid 24 / 26 / 3 0.270 0.230 0.285 1.554 (0.876–2.751); 0.128 0.934 (0.274–3.185); 1.000f
Clear cell 12 / 11 / 3 0.414 0.207 0.274 1.500 (0.679–3.314); 0.313 2.031 (0.575–7.179); 0.222f
Mixed 9 / 15 / 0 0.039 0.315 0.413 2.143 (0.919–4.997); 0.072 N/A
Solid tumor 9 / 9 / 0 0.388 0.988 0.988 1.286 (0.501–3.299); 0.600 N/A
Untyped 9 / 14 / 2 0.138 0.076 0.112 2.286 (0.990–5.280); 0.047 1.354 (0.304–6.038); 0.660f
19p13 rs2363956 G / t 0.49 All 56 / 154 / 62 115 / 244 / 105 0.196 0.399 0.451 1.271 (0.885–1.825); 0.193 1.009 (0.706–1.443); 0.959
Serous 17 / 53 / 26 0.235 0.139 0.169 1.531 (0.870–2.694); 0.137 1.270 (0.770–2.094); 0.348
Mucinous 7 / 18 / 5 0.559 0.738 0.837 1.083 (0.453–2.590); 0.858 0.684 (0.255–1.831); 0.650f
Endometrioid 13 / 28 / 12 0.948 0.971 0.979 1.104 (0.524–1.962); 0.967 1.001 (0.507–1.974); 0.998
Clear cell 8 / 11 / 7 0.719 0.911 0.906 0.741 (0.314–1.751); 0.493 1.260 (0.515–3.079); 0.612
Mixed 6 / 17 / 1 0.059 0.203 0.265 0.989 (0.383–2.551); 0.981 0.149 (0.020–1.114); 0.039f
Solid tumor 1 / 12 / 5 0.145 0.146 0.206 5.602 (0.737–42.578); 0.088f 1.315 (0.458–3.774); 0.574f
Untyped 4 / 15 / 6 0.512 0.476 0.579 1.730 (0.582–5.146); 0.473f 1.080 (0.420–2.774); 0.873

N/A not applicable

Statistically significant results for dominan and recessive model are highlighted in bold (p < 0.00714)

aUppercase denotes the more frequent allele in the control samples

bMAF, minor allele frequency calculated from the control samples

cThe order of genotypes: DD / Dd / dd (d is the minor allele in the control samples)

dDominant model: dd + Dd vs DD (d is the minor allele)

eRecessive model: dd vs Dd + DD (d is the minor allele)

fFisher exact test